PillTravoprost Ophthalmic Solution, 0.004%
Travoprost
1 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Mylan Pharmaceuticals Inc. | unknown | 2 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Jul 7, 2026RESOLVEDShortage resolved: Travoprost Ophthalmic Solution (Mylan Pharmaceuticals Inc., a Viatris Company)
Travoprost Ophthalmic Solution — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Ophthalmology.
- Jul 7, 2026SHORTAGEDrug shortage: Travoprost Ophthalmic Solution (Mylan Pharmaceuticals Inc., a Viatris Company)
Travoprost Ophthalmic Solution — reported in shortage by Mylan Pharmaceuticals Inc., a Viatris Company. Therapeutic category: Ophthalmology.
- Apr 1, 2022RECALLRecall (Class II): Travoprost Ophthalmic Solution, USP, 0.004%, 2.5 mL bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morg…
Subpotent Drug and Failed Impurities/Degradation Specifications: low out-of-specification results obtained for assay and high out-of-specification results for related substance impurities/degradation during routine stability testing. — Recalling firm: Mylan Pharmaceuticals Inc — Nationwide in the USA and Puerto Rico